scholarly journals Recurrence Features and Factors influencing Post-relapse Survival in Early-stage Endometrial Cancer after Adjuvant Radiotherapy

2022 ◽  
Vol 13 (1) ◽  
pp. 202-211
Author(s):  
Kang Ren ◽  
Wenhui Wang ◽  
Shuai Sun ◽  
Dunhuang Wang ◽  
Xiaoliang Liu ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Adjuvant Radiotherapy ◽  
Early Stage ◽  
Factors Influencing ◽  
Early Stage Endometrial Cancer

scholarly journals Adjuvant radiotherapy in early stage endometrial cancer

2011 ◽  
Vol 57 (4) ◽  
pp. 431-435
Author(s):  
Antonio Carlos Zuliani ◽  
AureaAkemi Cairo ◽  
Sérgio Carlos Barros Esteves ◽  
Carla Cristina dos Santos Watanabe ◽  
Maércio de OliveiraCunha ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Adjuvant Radiotherapy ◽  
Early Stage ◽  
Early Stage Endometrial Cancer

scholarly journals Adjuvant radiotherapy in early stage endometrial cancer

2011 ◽  
Vol 57 (4) ◽  
pp. 438-442 ◽  
Author(s):  
Antonio Carlos Zuliani ◽  
Aurea Akemi Cairo ◽  
Sérgio Carlos Barros Esteves ◽  
Carla Cristinados Santos Watanabe ◽  
Maércio de Oliveira Cunha ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Adjuvant Radiotherapy ◽  
Early Stage ◽  
Early Stage Endometrial Cancer

Adjuvant radiotherapy and survival outcomes in early-stage endometrial cancer: A multi-institutional analysis of 608 women

2006 ◽  
Vol 103 (2) ◽  
pp. 661-666 ◽  
Author(s):  
O. Kenneth Macdonald ◽  
William T. Sause ◽  
R. Jeffrey Lee ◽  
Christopher M. Lee ◽  
Mark K. Dodson ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Adjuvant Radiotherapy ◽  
Early Stage ◽  
Institutional Analysis ◽  
Survival Outcomes ◽  
Early Stage Endometrial Cancer

scholarly journals Adjuvant radiotherapy in early stage endometrial cancer

2011 ◽  
Vol 57 (4) ◽  
pp. 431-435
Author(s):  
Antonio Carlos Zuliani ◽  
AureaAkemi Cairo ◽  
Sérgio Carlos Barros Esteves ◽  
Carla Cristina dos Santos Watanabe ◽  
Maércio de OliveiraCunha ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Adjuvant Radiotherapy ◽  
Early Stage ◽  
Early Stage Endometrial Cancer

Chemotherapy for Early-stage High-risk Endometrial Cancer

2009 ◽  
Vol 05 (01) ◽  
pp. 71
Author(s):  
Thomas Hogberg ◽  
Keyword(s):  
Endometrial Cancer ◽  
Adjuvant Radiotherapy ◽  
Early Stage ◽  
Gynecologic Oncology ◽  
Response Rates ◽  
Drug Regimen ◽  
Good Prognosis ◽  
Phase Iii ◽  
Gynecologic Oncology Group ◽  
Early Stage Endometrial Cancer

Endometrial cancer generally has a good prognosis because most cases are diagnosed in stage I. It is possible to identify subgroups of patients with early-stage endometrial cancer with a poor prognosis. Despite a traditional generous use of adjuvant radiotherapy, these patients have five-year overall survival of approximately 80%. In this group there is a need for an effective systemic adjuvant therapy. Mainly based on superior response rates, doxorubicin + cisplatin was for many years the standard chemotherapy in endometrial cancer. Gynecologic Oncology Group (GOG)-177 was the first phase III study on chemotherapy in endometrial cancer that showed a survival advantage. Paclitaxel + doxorubicine + cisplatin was better than doxorubicine + cisplatin, but the toxicity of the three-drug regimen has precluded general acceptance. Paclitaxel + carboplatin has produced high response rates and is widely used, despite the lack of evidence based on randomised studies. GOG-122 compared doxorubicine + cisplatin with whole abdominal radiotherapy in advanced optimally operated endometrial cancer and showed that chemotherapy with doxorubicine + cisplatin resulted in superior survival. Two recent studies have compared adjuvant chemotherapy (cyclophosphamide + doxorubicine + cisplatin) with adjuvant radiotherapy in early-stage endometrial cancer. Both studies failed to show a difference between the treatments. Another study (NSGO-EC-9501/EORTC-55991) compared adjuvant radiotherapy plus chemotherapy with adjuvant radiotherapy, and showed better survival with the sequential combination.

Sign in / Sign up

Export Citation Format

Share Document